Clinical trials: Endocrine Disorder
Diabetes Mellitus
An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice
The objective of this survey on this registered product is to confirm the efficacy, and safety profile of Lantus in every day medical practice.
- Trial name
- NCT00576368
- Testing
- INSULIN GLARGINE
- Where
- Belgium
- Volunteers
- 4,464 people
- Sponsor
- Sanofi
Diabetes
Distinguishing Participant Groups Using Autonomic Dysfunction
A study population with impaired fasting glucose levels, impaired glucose tolerance levels and diabetes (with or without complications) along with healthy patients will be chosen as participants.
- Trial name
- NCT05199350
- Testing
- Device Name: ANSiscope
- Where
- India
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- DyAnsys, Inc.
AMN, AMN Gene Mutation
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
The course of AMN-related disabilities over time is poorly or incompletely understood due to a limited number of patients and lack of treatments.
- Conditions
- AMN, AMN Gene Mutation, X-ALD
- Trial name
- CYGNET (NCT05008874)
- Testing
- Natural History Observation
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- SwanBio Therapeutics, Inc.
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Diabetes Mellitus, Type 1
Apidra Children & Adolescents Study
Primary Objective: Evaluate the percentage of patients achieving glycosylated hemoglobin (HbA1c) level < 8% (in patients of 6-12 years old) and HbA1c level < 7.5% (in patients of 13-17 year old) at 6 and 12 months of treatment…
- Trial name
- NCT01202474
- Testing
- INSULIN GLULISINE, INSULIN GLARGINE
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus
To compare the early pharmacokinetic exposure of URAL and insulin lispro (ILisp).
- Trial name
- NCT02206568
- Testing
- URAL
- Where
- Germany
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes.
- Trial name
- SUSTAIN 11 (NCT03689374)
- Testing
- Semaglutide, Insulin aspart, Insulin glargine U100
- Where
- 210 sites in Bosnia and Herzegovina, Bulgaria and 19 more
- Volunteers
- 2,274 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart (BIAsp) 70 and/or BIAsp 50 with biphasic human insulin (BHI) 30 treatment.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01520818
- Testing
- biphasic insulin aspart 50, biphasic insulin aspart 70, biphasic human insulin 30
- Where
- 77 sites in Belgium, France and 3 more
- Volunteers
- 666 people
- Sponsor
- Novo Nordisk A/S
Diabetic Foot Ulcer
The Purpose of This Study is to Assess Clinical Efficacy and Safety of Berovenal® Intended to Promote Treatment and to Expedite Chronic Diabetic Foot Ulcer Healing
The goal of this clinical investigation is to evaluate clinical efficacy of medical device Berovenal® intended to promote treatment and to expedite healing of chronic diabetic foot ulcer in male or female subjects aged 18-85…
- Trial name
- NCT06584617
- Testing
- Berovenal®, NU-GEL Hydrogel with Alginate
- Where
- 9 sites in Germany, Poland
- Volunteers
- 66 people
- Sponsor
- VULM s.r.o.
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Type 2 Diabetes
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
This study will assess the initial safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-8655, after single and multiple daily oral administrations to participants with Type 2 Diabetes (T2DM).
- Trial name
- NCT01640873
- Testing
- MK-8655
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Thyroid Eye Disease
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants.
- Trial name
- NCT05002998
- Testing
- Teprotumumab
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 313 people
- Sponsor
- Amgen
Ovarian Cancer
Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer
The purpose of this study is to determine the maximum tolerated dose of Genexol®-PM plus Carboplatin and evaluate the efficacy and safety of Genexol®-PM plus Carboplatin regimen in subjects with advanced ovarian cancer.
- Trial name
- NCT00877253
- Testing
- Genexol-PM 220mg/㎡, Carboplatin 5AUC, Genexol-PM 260mg/㎡, Carboplatin 5AUC, Genexol-PM 300mg/㎡, Carboplatin 5AUC
- Volunteers
- 18 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Diabetes Mellitus, Type 2
A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components
This is a phase-1, single center, open-label, randomized, single-dose, 2-way crossover study. The objective of the study is to compare the pharmacokinetic properties after co-administration of Repaglinide 2mg and Metformin…
- Trial name
- NCT01780051
- Testing
- Repaglinide/Metformin combination, Repaglinide, Metformin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dalim BioTech Co., Ltd.
Diabetes Mellitus, Type 2
The TANTALUS® II for the Treatment of Type 2 Diabetes
Evaluation of the safety and efficacy of gastric contractility modulation (GCM) stimulation using the TANTALUS System in the improvement of glycemic control measured by changes in HbA1c.
- Trial name
- Crossover (NCT01303302)
- Testing
- Tantalus System
- Where
- 7 sites in Austria, Germany and 2 more
- Volunteers
- 51 people
- Sponsor
- MetaCure (USA), Inc.
Diabetic Retinopathy
Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic eye disease (DED), the leading cause of vision loss and blindness in working-age adults.
- Trial name
- NCT03078231
- Testing
- Color fundus photography, Mydriatic Agent
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Eyenuk, Inc.
Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of PPB-R-203-Based Meal Versus TK9-Based Meal in 20 Patients With Diabetes
To evaluate the efficacy of PPB-R-203-Based Meal and TK9-Based Meal on blood glucose control in 20 patients with diabetes for 2 days.
- Trial name
- NCT01065402
- Testing
- PPB-R-203-Based Meal, TK9-Based Meal
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Pharma Power Biotec Co., Ltd.
Diabetes Mellitus, Type 2
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 52-week clinical study is designed as an open label, long-term study aimed to evaluate the safety of vildagliptin in…
- Trial name
- NCT00325429
- Testing
- Vildagliptin
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall…
- Trial name
- NCT00099931
- Testing
- vildagliptin
- Where
- Germany
- Volunteers
- 254 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.
- Trial name
- NCT05184231
- Sponsor
- Ipsen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.